JAMA · 2015 · 14 citations · 1 references
PharmacyPharmaceutical PolicyCompetition PolicyDrug Approval ProcessesPharmaceutical RegulationBiosimilar RegulationDrug ApprovalPharmaceutical EconomicsPharmaceutical GovernancePharmaceutical MarketingResearch CompetitionBiosimilar CompetitionCompetitive EnvironmentGeneric Drug PricingGeneric Medicine Market CompetitionMarket Access For BiosimilarsPharmaceutical Market CompetitionRegulatory Frameworks For Biosimilars
This Viewpoint discusses how the competition created by biosimilars is different from competition from generic drugs and proposes ways in which public policy might increase the competitive benefits of biosimilars.
1